Standigm Races AI Rivals To Become Global Discovery Contender

The South Korean AI-driven drug discovery venture is vying with global rivals in the space to show concrete validation of its approaches in partnered projects, while eyeing international expansion and new fundraising, its CEO says.

AI
Pursuing Discovery Of First-In-Class, Novel Molecules • Source: Shutterstock

With a goal to offer a new standard in novel drug discovery using artificial intelligence (AI) technology, South Korea's Standigm Inc. is progressing multiple co-research projects with pharma and other partners, and is poised to establish a new laboratory facility this year to further validate the competitiveness of its AI-designed molecules.

Founded in 2015, privately-held Standigm has developed what it says is an automated and all-encompassing AI approach, using experts in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia